The Manufacturers Life Insurance Company increased its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 122.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 356,058 shares of the company's stock after acquiring an additional 195,719 shares during the quarter. The Manufacturers Life Insurance Company's holdings in Sanofi were worth $17,180,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of SNY. Synergy Asset Management LLC bought a new position in Sanofi during the 4th quarter worth about $25,000. McClarren Financial Advisors Inc. grew its holdings in shares of Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after buying an additional 543 shares in the last quarter. Lee Danner & Bass Inc. acquired a new stake in Sanofi in the 4th quarter valued at approximately $31,000. Bessemer Group Inc. lifted its stake in Sanofi by 59.8% in the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after acquiring an additional 242 shares in the last quarter. Finally, Sierra Ocean LLC bought a new stake in Sanofi in the 4th quarter valued at approximately $44,000. Institutional investors and hedge funds own 14.04% of the company's stock.
Sanofi Trading Down 0.5 %
Shares of Sanofi stock traded down $0.23 on Friday, hitting $50.29. The stock had a trading volume of 1,238,688 shares, compared to its average volume of 2,772,681. The stock has a 50 day moving average of $54.37 and a 200 day moving average of $52.03. The firm has a market capitalization of $127.05 billion, a P/E ratio of 20.20, a PEG ratio of 1.01 and a beta of 0.55. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.
Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The business had revenue of $10.41 billion during the quarter, compared to analysts' expectations of $9.79 billion. During the same period last year, the company posted $1.78 earnings per share. The business's quarterly revenue was down 11.0% on a year-over-year basis. Sell-side analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.
Sanofi Increases Dividend
The company also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be paid a $2.0369 dividend. This is a positive change from Sanofi's previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. This represents a yield of 3.1%. Sanofi's dividend payout ratio (DPR) is 57.14%.
Analysts Set New Price Targets
SNY has been the topic of several analyst reports. BNP Paribas assumed coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target on the stock. Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. The Goldman Sachs Group started coverage on Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective for the company. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Finally, Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $63.33.
Get Our Latest Report on SNY
About Sanofi
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
See Also
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
